Autopsy report · NCT03940352
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Cause of deathFunding or business
“Business decision”
Life of this trial
- Registered 2 months before it started.
- Ran for about 5 years 2 months before it stopped.
- 52 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Acute Myeloid Leukemia (AML); High-risk Myelodysplastic Syndrome (MDS)
- Interventions
- HDM201; MBG453; Venetoclax
- Participants
- 52
- Sites
- 9
- Countries
- Australia, Finland, Germany, Italy, Singapore, Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.